 |
 |
 |
|
No Clinically Significant Interaction of MK-8408 With the HIV Medications Dolutegravir, Raltegravir, Rilpivirine, and Tenofovir Disoproxil Fumarate
|
|
|
Reported by Jules Levin
The 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy
Washington, DC June 8-10, 2016
Wei Gao; Jennifer Talaty; Leticia Arrington; Graig Garrett; William L. Marshall; Nancy Kim*; Eugene E. Marcantonio *Corresponding author
Merck & Co., Inc., Kenilworth, NJ, USA






|
|
|
 |
 |
|
|